Cargando…
Trial of Tramadol Plus Gabapentin for Opioid Detoxification
BACKGROUND: Substance abuse or drug addiction is one of the most important health issues in every society, which can lead to physical and mental problems. OBJECTIVES: This study aimed to compare the efficacy of tramadol plus gabapentin versus methadone use in the treatment of opiate withdrawal. PATI...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341495/ https://www.ncbi.nlm.nih.gov/pubmed/25763266 http://dx.doi.org/10.5812/ircmj.18202 |
_version_ | 1782359196627369984 |
---|---|
author | Ziaaddini, Hassan Ziaaddini, Ahmad Asghari, Neda Nakhaee, Nozar Eslami, Mahin |
author_facet | Ziaaddini, Hassan Ziaaddini, Ahmad Asghari, Neda Nakhaee, Nozar Eslami, Mahin |
author_sort | Ziaaddini, Hassan |
collection | PubMed |
description | BACKGROUND: Substance abuse or drug addiction is one of the most important health issues in every society, which can lead to physical and mental problems. OBJECTIVES: This study aimed to compare the efficacy of tramadol plus gabapentin versus methadone use in the treatment of opiate withdrawal. PATIENTS AND METHODS: Consenting male subjects who fulfilled the DSM-4 criteria for opiate dependence syndrome (opium, residue, and heroin) were randomly assigned in two groups to receive tramadol plus gabapentin or methadone. Assessment tools were Adjective Rating Scale for Withdrawal (ARSW), Clinical Opiate Withdrawal Scale (COWS) and Visual Analogue craving Scale (VAS). Fifty-nine subjects were enrolled and evaluated on days 1, 2, 3, 4, 6, and 8 during their 10 days of admission. Twenty-nine participants received methadone and the other 30 received tramadol plus gabapentin for their treatment. RESULTS: Mean (SD) age of the patients in methadone group and tramadol plus gabapentin group were 33.9 (7.1) and 32.4. (8.1), respectively (P = 0.462). The overall ARSW (P value = 0.263) and COWS (P = 0.862) scores between the two groups were comparable. The differences in the VAS score for craving between the two groups was marginally significant (P = 0.057). The highest VAS score was at the third day of admission in both groups and it was generally higher in methadone group. CONCLUSIONS: The severity of withdrawal syndrome in two groups was not significantly different. The craving was higher in the group receiving methadone from the second day of admission even though the usage amount was higher in the tramadol plus gabapentin group. The findings of this study suggest that the combination of tramadol plus gabapentin is an efficient method for opioid detoxification. |
format | Online Article Text |
id | pubmed-4341495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-43414952015-03-11 Trial of Tramadol Plus Gabapentin for Opioid Detoxification Ziaaddini, Hassan Ziaaddini, Ahmad Asghari, Neda Nakhaee, Nozar Eslami, Mahin Iran Red Crescent Med J Research Article BACKGROUND: Substance abuse or drug addiction is one of the most important health issues in every society, which can lead to physical and mental problems. OBJECTIVES: This study aimed to compare the efficacy of tramadol plus gabapentin versus methadone use in the treatment of opiate withdrawal. PATIENTS AND METHODS: Consenting male subjects who fulfilled the DSM-4 criteria for opiate dependence syndrome (opium, residue, and heroin) were randomly assigned in two groups to receive tramadol plus gabapentin or methadone. Assessment tools were Adjective Rating Scale for Withdrawal (ARSW), Clinical Opiate Withdrawal Scale (COWS) and Visual Analogue craving Scale (VAS). Fifty-nine subjects were enrolled and evaluated on days 1, 2, 3, 4, 6, and 8 during their 10 days of admission. Twenty-nine participants received methadone and the other 30 received tramadol plus gabapentin for their treatment. RESULTS: Mean (SD) age of the patients in methadone group and tramadol plus gabapentin group were 33.9 (7.1) and 32.4. (8.1), respectively (P = 0.462). The overall ARSW (P value = 0.263) and COWS (P = 0.862) scores between the two groups were comparable. The differences in the VAS score for craving between the two groups was marginally significant (P = 0.057). The highest VAS score was at the third day of admission in both groups and it was generally higher in methadone group. CONCLUSIONS: The severity of withdrawal syndrome in two groups was not significantly different. The craving was higher in the group receiving methadone from the second day of admission even though the usage amount was higher in the tramadol plus gabapentin group. The findings of this study suggest that the combination of tramadol plus gabapentin is an efficient method for opioid detoxification. Kowsar 2014-12-29 /pmc/articles/PMC4341495/ /pubmed/25763266 http://dx.doi.org/10.5812/ircmj.18202 Text en Copyright © 2015, Iranian Red Crescent Medical Journal. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. |
spellingShingle | Research Article Ziaaddini, Hassan Ziaaddini, Ahmad Asghari, Neda Nakhaee, Nozar Eslami, Mahin Trial of Tramadol Plus Gabapentin for Opioid Detoxification |
title | Trial of Tramadol Plus Gabapentin for Opioid Detoxification |
title_full | Trial of Tramadol Plus Gabapentin for Opioid Detoxification |
title_fullStr | Trial of Tramadol Plus Gabapentin for Opioid Detoxification |
title_full_unstemmed | Trial of Tramadol Plus Gabapentin for Opioid Detoxification |
title_short | Trial of Tramadol Plus Gabapentin for Opioid Detoxification |
title_sort | trial of tramadol plus gabapentin for opioid detoxification |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341495/ https://www.ncbi.nlm.nih.gov/pubmed/25763266 http://dx.doi.org/10.5812/ircmj.18202 |
work_keys_str_mv | AT ziaaddinihassan trialoftramadolplusgabapentinforopioiddetoxification AT ziaaddiniahmad trialoftramadolplusgabapentinforopioiddetoxification AT asgharineda trialoftramadolplusgabapentinforopioiddetoxification AT nakhaeenozar trialoftramadolplusgabapentinforopioiddetoxification AT eslamimahin trialoftramadolplusgabapentinforopioiddetoxification |